OpenAI bought a startup whose agents chase drug trial delays.
OpenAI said on Tuesday it is buying Orchestra Bio, a four-year-old software startup. Its agents track trial budgets and reschedule studies when a manufacturing batch fails. The price was not disclosed, and the team joins OpenAI's Rosalind life sciences unit.
Why it mattersDrug development stalls on paperwork and scheduling as much as on the science itself. OpenAI is buying the dull middle of that work rather than only selling models for it.
Read in the app — free, in 9 languages
Related stories
Seller robots padded their listings until buyers picked useless tools.2026-10-21Mistral's new voice models listen for when you stop talking.
2026-10-21Anthropic's draft listing shows a loss bigger than its revenue.
2026-10-21China's tech giants ordered far more chips than Nvidia can make.
2026-10-20The US Army wants AI agents that spread through enemy networks.
2026-10-20